Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) CEO Sells $490,313.36 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) CEO Sean Bohen sold 52,328 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total transaction of $490,313.36. Following the completion of the sale, the chief executive officer now owns 298,836 shares in the company, valued at $2,800,093.32. This represents a 14.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock opened at $6.75 on Friday. The company has a market capitalization of $386.76 million, a price-to-earnings ratio of -3.08 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a 52-week low of $6.24 and a 52-week high of $16.77. The company has a 50-day simple moving average of $10.70 and a two-hundred day simple moving average of $11.86.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $27.00.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of OLMA. Barclays PLC lifted its holdings in Olema Pharmaceuticals by 105.0% during the third quarter. Barclays PLC now owns 94,915 shares of the company’s stock worth $1,133,000 after acquiring an additional 48,614 shares during the period. Conway Capital Management Inc. bought a new stake in shares of Olema Pharmaceuticals during the 3rd quarter worth $119,000. XTX Topco Ltd boosted its holdings in shares of Olema Pharmaceuticals by 103.4% in the 3rd quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock worth $302,000 after buying an additional 12,878 shares during the last quarter. EP Wealth Advisors LLC grew its position in Olema Pharmaceuticals by 5.2% during the third quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock valued at $581,000 after buying an additional 2,407 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Olema Pharmaceuticals by 10.8% during the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after buying an additional 97,428 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.